AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7027873
Drug: Oral bromhexine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bromhexine, 32 mg/day
Trial: 24452943
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with optimal mineral-content diet (diet group, 27 subjects)
Trial: 24452943
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment without dietary change (control group, 18 subjects)
Trial: 24452943
Drug: Overall antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall antihypertensive treatment
Trial: 18681100
Drug: Twice-weekly strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly strength training over 2 years
Trial: 8717556
Drug: 100mg aspirin
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin daily
Trial: 24791969
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 μg/kg
Trial: 24791969
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.15 ml/kg (Control Group C)
Trial: 23261045
Drug: High-Dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose (HD) trivalent inactivated influenza vaccine (60μg of hemagglutinin per strain)
Trial: 23261045
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose (SD) trivalent inactivated influenza vaccine (15μg of hemagglutinin per strain)
Trial: 23261045
Drug: High-Dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose (HD) trivalent inactivated influenza vaccine
Trial: 23261045
Drug: Standard Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Dose (SD) trivalent inactivated influenza vaccine
Trial: 20880602
Drug: Alpha lipoic
RxNorm normalized name: Alpha Lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha lipoic acid therapy (ALA)
Trial: 15146341
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy in the early (prepsychotic) prodromal state
Trial: 15146341
Drug: Amisulpride treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride treatment in the late prodromal (early psychotic) state
Trial: 15146341
Drug: Normal clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal clinical treatment
Trial: 2569848
Drug: Succinylcholine (Suc)
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (Suc) infusion
Trial: 4817160
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (25 g) in the morning
Trial: 4817160
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose (25 g) in the afternoon
Trial: 31634193
Drug: Recombinant gp120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant gp120 protein vaccine (Vax004 clinical trial)
Trial: 21527603
Drug: Cyclic parenteral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic parenteral nutrition (PN) with DEHP exposure
Trial: 18772101
Drug: Prostaglandin analogues
RxNorm normalized name: Prostaglandin analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin analogues administered by non-invasive routes
Trial: 8839903
Drug: CEF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (cyclophosphamide 600 mg/sqm i.v., epidoxorubicin 60 mg/sqm i.v. and fluorouracil 600 mg/sqm i.v.)
Trial: 8839903
Drug: DES-CEF (diethylstilbestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES-CEF (diethylstilbestrol 1 mg orally days 1-3, CEF on day 4)
Trial: 1948120
Drug: Simultaneous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous chemotherapy with 25 mg/m2 of 4-epirubicin intravenously for 18 weeks after surgical castration.
Trial: 1948120
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy with surgical castration and long-term administration of flutamide without initial chemotherapy.
Trial: 6842023
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) therapy
Trial: 31960396
Drug: Aromatherapy (20-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (20-min inhalation of essential oil every night for 4 weeks)
Trial: 31960396
Drug: Control (20-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (20-min inhalation of sweet almond oil every night for 4 weeks)
Trial: 22739394
Drug: Nevirapine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (50 mg), Stavudine (6 mg), Lamivudine (30 mg) in fixed dose combination tablet (Triomune Baby)
Trial: 14678081
Drug: SR 49059
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 49059 (0, 25, 75, or 200 mg)
Trial: 9675622
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg three times a day with 125 mg MK-0591 twice a day
Trial: 9675622
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg three times a day with placebo for MK-0591
Trial: 9675622
Drug: MK-0591 125
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 125 mg twice a day with placebo for ibuprofen
Trial: 9675622
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Ibuprofen and MK-0591)
Trial: 15642960
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with sulfadoxine-pyrimethamine plus artesunate
Trial: 11320018
Drug: Initial medication
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medication (n = 307)
Trial: 9263611
Drug: Ipriflavone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (600 mg/day, T.D.D.) with 500 mg/day of calcium
Trial: 7950502
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 500 mg/day of calcium
Trial: 7659481
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (DTaP)
Trial: 8426770
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pertussis vaccine (DTwP)
Trial: 3723990
Drug: Doxorubicin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (15 mg/m2, 4 times per 48 h)
Trial: 21077043
Drug: Continuous blood
RxNorm normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous blood purification (CBP) treatment (CVVH)
Trial: 10048679
Drug: Azithromycin suspension
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin suspension for 5 days
Trial: 10048679
Drug: Amoxicillin-clavulanate for
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate for 10 days (for those <5 years)
Trial: 10048679
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate suspension (for those >=5 years)
Trial: 10048679
Drug: Healthy control
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy control children (no treatment)
Trial: 2289214
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg twice a day for 21 days
Trial: 27624622
Drug: Neladenoson bialanate
RxNorm normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neladenoson bialanate 30 mg single dose
Trial: 27624622
Drug: Neladenoson bialanate
RxNorm normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neladenoson bialanate 10 mg for 7 days
Trial: 27624622
Drug: Neladenoson bialanate
RxNorm normalized name: Neladenoson bialanate
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neladenoson bialanate 20 mg for 7 days
Trial: 20682612
Drug: Oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-acetylcysteine (NAC) with intravenous hydration
Trial: 20682612
Drug: Intravenous hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydration only
Trial: 19246588
Drug: Prandial strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prandial strategy (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l)
Trial: 19246588
Drug: Basal strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal strategy (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l)
Trial: 15146410
Drug: Full-dosage etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Full-dosage etanercept (25 mg twice weekly) plus anakinra (100 mg/day)
Trial: 15146410
Drug: Etanercept only
RxNorm normalized name: Etanercept only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept only (25 mg twice weekly)
Trial: 15146410
Drug: Half-dosage etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Half-dosage etanercept (25 mg once weekly) plus anakinra (100 mg/day)
Trial: 9408807
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg once daily for 15 days) with terfenadine (60 mg twice daily for 8 days)
Trial: 9408807
Drug: Terfenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (60 mg twice daily for 8 days) alone
Trial: 7969324
Drug: Perioperative nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative nutritional support (intravenous solution enriched with 35% branched-chain amino acids, dextrose, and lipid emulsion for 14 days)
Trial: 3297129
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid 20 mg/d if marrow blasts ≤ 5% or cytosine arabinoside 10 mg/d subcutaneously on 6 d/week if marrow blasts 6-30%, retinoic acid added after 12 weeks
Trial: 3297129
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving conventional supportive therapy
Trial: 30022571
Drug: isCGM group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isCGM group (26 participants, blinded for SMBG, insulin dosing based on isCGM)
Trial: 30022571
Drug: SMBG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMBG group (20 participants, blinded for isCGM, insulin dosing based on SMBG)
Trial: 27222271
Drug: CEP-26401 (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP-26401 (0.02 to 5 mg single dose; 0.02 to 0.5 mg once daily multiple dosing)
Trial: 20504165
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (7vPnC) with 1 mg of CPG 7909 adjuvant
Trial: 10648327
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion (Control)
Trial: 6094448
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later (Group A)
Trial: 6094448
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g intravenous at the induction of anaesthesia, the beginning of the resection, 4 and 8 h later, associated with ornidazole or metronidazole 0.5 g intravenous at the induction of anaesthesia and 0.5 g intravenous with the last injection of cefotaxime (Group B)
Trial: 23475451
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (N=97) including education about blood‐borne diseases and referrals for testing and vaccinations
Trial: 21176079
Drug: BCG maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks as induction therapy, followed by three once-weekly instillations at 3, 6, 12 and 18 months)
Trial: 21176079
Drug: BCG non-maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG non-maintenance therapy (81 mg, intravesically instilled once weekly for 6 weeks)
Trial: 21176079
Drug: Epirubicin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin therapy (40 mg, intravesically instilled nine times)
Trial: 20205984
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg isoflavones
Trial: 17413839
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg isoflavones)
Trial: 21689775
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (Tio) plus transdermal tulobuterol (Tulo) 18 μg once daily plus 2 mg once daily for 4 weeks
Trial: 21689775
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (Tio) 18 μg once daily for 4 weeks
Trial: 21689775
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (Tio) plus transdermal tulobuterol (Tulo)
Trial: 11467343
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) infusion of α-Lipoic acid (LA)
Trial: 11467343
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of α-Lipoic acid (LA)
Trial: 9663825
Drug: CDP571 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 (5 mg/kg, single intravenous infusion)
Trial: 8245892
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of acyclovir twice daily
Trial: 8245892
Drug: Episodic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic treatment (ES)
Trial: 8245892
Drug: Open-label acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label acyclovir suppressive therapy
Trial: 3516408
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (DHE) nasal spray, dosage 1 mg
Trial: 27898164
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg IV)
Trial: 25842461
Drug: SRP combined
RxNorm normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel and doxycycline for 2 weeks
Trial: 25842461
Drug: SRP combined
RxNorm normalized name: SRP 299
DrugBank: SRP 299 (DB05440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP combined with prescription-tray application of 1.7% hydrogen peroxide gel
Trial: 20124186
Drug: Enzastaurin 500
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin 500 mg/d (1,125 mg loading dose, day 1)
Trial: 20124186
Drug: Lomustine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomustine (100 to 130 mg/m2, day 1)
Trial: 10081852
Drug: BCG (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (120 mg, Danish strain 1331)
Trial: 2194987
Drug: Phenylpropanolamine 25
RxNorm normalized name: phenylpropanolamine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine 25 mg
Trial: 665568
Drug: 14.2 g
RxNorm normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.2 g of hemicellulose supplement per subject per day
Trial: 665568
Drug: 14.2 g
RxNorm normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.2 g of cellulose supplement per subject per day
Trial: 665568
Drug: 14.2 g
RxNorm normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.2 g of pectin supplement per subject per day
Trial: 665568
Drug: 14.2 g
RxNorm normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.2 g of pectin plus 1.3 g of zinc
Trial: 665568
Drug: 14.2 g
RxNorm normalized name: ZINC OXIDE 14.2 g in 100 mL TOPICAL LOTION [COOLA Mineral Body SPF 30 Tropical Coconut]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.2 g of pectin plus 9.3 g of zinc
Trial: 665568
Drug: 4.2 g
RxNorm normalized name: CHLORINE 4.2 g in 100 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 g of pectin plus 1.3 g of zinc
Trial: 665568
Drug: 4.2 g
RxNorm normalized name: CHLORINE 4.2 g in 100 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 g of pectin plus 9.3 g of zinc
Trial: 20878653
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant (5 mL of liquid fibrin sealant sprayed before drains insertion)
Trial: 19338151
Drug: Ginaton (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginaton (0.5 mg/kg)
Trial: 10201475
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 microg/h continuous infusion after an initial 100-microg bolus)
Trial: 7781346
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg methylprednisolone
Trial: 7781346
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg methylprednisolone
Trial: 2150527
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg GBR 12909
Trial: 2150527
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg GBR 12909
Trial: 2150527
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg GBR 12909
Trial: 2150527
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg GBR 12909
Trial: 2150527
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg GBR 12909
Trial: 2150527
Drug: GBR 12909
RxNorm normalized name: GBR-12783
DrugBank: GBR-12783 (DB17027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBR 12909 (various doses)
Trial: 376079
Drug: Brompton mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brompton mixture (containing morphine, cocaine, ethyl alcohol, syrup BP, and chloroform water) administered orally
Trial: 376079
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone in a flavoured aqueous solution administered orally
Trial: 23812862
Drug: Intravenous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous interferon (IFN) administered during the anhepatic phase of liver transplantation, along with weight-based ribavirin and subcutaneous IFN at time of incision.
Trial: 23812862
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intravenous interferon).
Trial: 20932360
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care cognitive behaviour therapy (CBT) - 10 sessions
Trial: 20932360
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (second phase)
Trial: 20932360
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (third phase)
Trial: 20932360
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care cognitive behaviour therapy (CBT)
Trial: 23423871
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene 0.1% cream